System and method for treatment of hemorrhagic stroke

Abstract

Embodiments of the invention provide apparatus, methods and systems for delivering treatments and for medications to the site of an aneurysm (SOA). One embodiment of a method comprises delivering a neural growth stimulating factor (NGSF) to the site of the aneurysm to grow new nerve cells and / or stimulate the regeneration of damaged nerve cells. The NGSF may be delivered in a carrier such as a gel which can be selected to allow for long term delivery of the NGSF to the SOA. In many embodiments, the NGSF may be delivered to the SOA using a microcatheter based system which includes a microcatheter that can be advanced in the cerebral vasculature. The microcatheter may also be used to delivery occlusive element to the SOA such as occlusive coils or balloon which promote clotting and reduce bleeding at the SOA and together with the carrier allow for long term release of NGSF.

Description

RELATED APPLICATIONS[0001]This application is a divisional of U.S. patent application Ser. No. 13 / 529,608, filed Jun. 21, 2012, now U.S. patent Ser. No. ______, which claims the benefit of priority of Provisional U.S. Patent Application Ser. No. 61 / 503,439, filed Jun. 30, 2011; the contents of which are fully incorporated herein by reference.BACKGROUND1. Field of the Invention[0002]Embodiments of the invention relate to drug delivery devices and methods of use thereof. More specifically, embodiments of the invention relate to drug delivery devices and methods for delivering neural growth and protective factors to the site of a cerebral aneurysm.[0003]Strokes afflict millions of Americans each year and result in significant morbidity and mortality. During a stroke, one or more areas of the brain can be damaged. Depending upon the area affected, a person may lose the ability to move one side of the body, the ability to speak, or a number of other functions. The damage may be temporary...

AI Technical Summary

Benefits of technology

The patent describes a method for treating cerebral aneurysms by delivering a therapeutic agent called glial cell derived neurotrophic factor (GDNF) to the affected site. The therapeutic agent is delivered through a gel that is saturated with oxygen and has low viscosity. The gel acts as a drug depot or reservoir to provide extended delivery of the therapeutic agents to the tissue at the affected site. The gel can be designed to release the therapeutic agents quickly or over a longer period of time depending on the needs of the patient. The method can also involve delivering embolization inducing coils or a vascular clip to treat the aneurysm and the gel can be positioned near the coils or clip to provide a rapid localized delivery of the therapeutic agents. Overall, the method allows for targeted treatment of cerebral aneurysms with a therapeutic agent that can promote brain cell survival and reduce the risk of hemorrhage.

Problems solved by technology

Strokes afflict millions of Americans each year and result in significant morbidity and mortality.

During a stroke, one or more areas of the brain can be damaged.

The damage may be temporary or permanent, and the function may be partially or completely lost.

Such methods, however, have limited use after rupture for treating local brain tissue that has been affected by ischemia and hypoxia resulting from the hemorrhage.

Such effects can result in neural cell death at the ischemic site in turn causing loss of brain function at the affected cite.

Images